8-K
filed October 15, 2024, 7:59 PM ET
ticker AXIM
CIK 0001514946
other material
confidence high
sentiment negative
materiality 0.80
AXIM BIOTECHNOLOGIES, INC. (AXIM): M&A transaction — Change in control at AXIM Biotechnologies; CEO John Huemoeller dies, Catalina Valencia named President
AXIM BIOTECHNOLOGIES, INC.
- Kettner Investments acquires control via Series C Preferred Stock transfer from Juniper & Ivy and Medical Marijuana, Inc.
- CEO/President John W. Huemoeller II died Oct 12 due to illness; board appointed Catalina Valencia as President on Oct 9.
- Valencia also appointed Series C Director to fill vacancy from Huemoeller's death; she previously founded Sapphire Biotech.
- Series C stock transferred from Juniper to MJNA to satisfy $515K note, then to Kettner to waive $1.09M notes plus $66K interest.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Catalina Valencia was appointed as Series C Director at AXIM BIOTECHNOLOGIES, INC..
- Action
- appointed
- Role
- Series C Director
Exact text from the filing
effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John W. Huemoeller II departed as President and CEO at AXIM BIOTECHNOLOGIES, INC..
- Action
- unable to serve
- Role
- President and CEO
Exact text from the filing
Due to the fact that the Company's President and CEO, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John W. Huemoeller II departed as Series C Director at AXIM BIOTECHNOLOGIES, INC..
- Action
- died
- Role
- Series C Director
Exact text from the filing
On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Catalina Valencia was appointed as President at AXIM BIOTECHNOLOGIES, INC..
- Action
- appointed
- Role
- President
Exact text from the filing
on October 9, 2024, the Company’s board of directors appointed Catalina Valencia as the Company’s new President.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
AXIM BIOTECHNOLOGIES, INC. underwent a change of control involving Kettner Investments, LLC (closed 2024-10-15).
- Action
- change of control
- Counterparty
- Kettner Investments, LLC
- Closing
- 2024-10-15
Exact text from the filing
Effective October 15, 2024, Juniper & Ivy Corporation (“Juniper”), the holder of all 500,000 shares of the Company's Series C Preferred Stock, entered into an agreement with Medical Marijuana, Inc. ("MJNA") and Kettner Investments, LLC ("Kettner") regarding the transfer and assignment of the Series C Preferred Stock (the "Agreement").
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.